Among them, two patients with EBV− CD4+ TFH+ PTCL and EBV+ CD4+ CD30+ large-cell PTCL-NOS, one EBV− CD8+ sALCL, and two sEBV+ CD8+ TCLs showed a lethal progressive clinical course within 13 months. This evidence concerns the gene CD8A and mature T-cell and NK-cell non-Hodgkin lymphoma.